SBMFF News and Press, Sino Biopharmaceutical Ltd From 12/06/20

Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China HONG KONG, Dec 7, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., L...

Sino Biopharmaceutical Announces 2020 Third Quarterly Results HONG KONG, Nov 30, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmac...

Revenue Increases by 1.0% to RMB12.648 Billion Underlying Profit up 5.2% to RMB1.761 Billion HONG KONG, Aug 28, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research ...

Revenue was approximately RMB6.22 Billion; Profit Attributable to Owners of the Parent was approximately RMB862 Million HONG KONG, May 28, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:117...

HONG KONG, May 26, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("the Group") (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug ...

HONG KONG, May 19, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on phase II study on clinical efficacy and safety of Penpulimab (AK...

Revenue Climbs 16.0% to RMB24.23 billion Underlying Profit Up 10.2% to RMB3.13 billion; Achieves an outstanding R&D performance and obtains 28 production approvals HONG KONG, Mar 30, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with ...

Deals and Financings Beijing's BeiGene ([[BGNE]]; HK: 06160) will receive a $150 million termination payment from Celgene (CELG) because Celgene will end its $1.4 billion partnership for ex-China rights to BeiGene's PD-1 candidate. The original deal included a provision that BeiGene's ti...